The Evolving Biosimilar Policy Landscape in the Middle East
August 16, 2023
Get Instant Access
Biosimilar adoption level can vary depending on factors such as the specific healthcare systems, the regulatory framework, physician and patient acceptance, and the competitor landscape. In the Middle East and Africa, careful consideration of applicable market archetypes, stakeholder awareness, and strategic partnerships are necessary to realize the full benefits of biosimilars for healthcare cost management. In this paper, we explore the current status of Algeria, Egypt, Jordan, Morocco, Saudi Arabia, South Africa, Tunisia, and the UAE to determine their current positioning and understand the future outlook of the biopharmaceuticals segment in the Middle East & Africa.
